1706 completed, 435 unknown, 185 terminated, 141 recruiting. 2698 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2698 | Completed 1706, Unknown 435, Terminated 185, Recruiting 141, Withdrawn 100, Not yet recruiting 69, Active not recruiting 43, Enrolling by invitation 15, Suspended 4 |
Follow Endocrine System Diseases: new trials by email Literature Review of Endocrine System Diseases trials Research Report on Endocrine System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Discontinuation of Low-Dose Levothyroxine in Older Adults With Subclinical Hypothyroidism Levothyroxine Pill, Placebo - Hypothyroidism | Phase 4 | Not yet recruiting | Spyridoula Maraka | 138 | 2027-10-01 | 2026-08-26 |
| Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD Naoxintong Capsule, Placebo - Diabetic Nephropathy | Phase 4 | Not yet recruiting | Chen Xiangmei | 410 | 2027-03-01 | 2026-07-13 |
| SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy Spironolactone (drug), Candesartan 8mg, Hydrochlorothiazide (HCTZ) 25 milligrams. - Hypertension | Phase 4 | Not yet recruiting | Ottawa Hospital Research Institute | 30 | 2027-01-01 | 2026-10-14 |
| Insulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes Insulin icodec - Type 2 Diabetes | Phase 4 | Not yet recruiting | Xi'an International Medical Center Hospital | 462 | 2027-01-01 | 2026-08-05 |
| Efficacy of Topical Lidocaine Gel vs. Oral Duloxetine for Painful Diabetic Peripheral Neuropathy Topical Lidocaine 2% Gel, Duloxetine (60 MG) - Painful Diabetic Neuropathy (PDN), Diabetic Neuropathies | Phase 4 | Not yet recruiting | Wah Medical college , POF hospital | 80 | 2026-12-01 | 2026-09-02 |
| Pharmacogenetics of Response to Sitagliptin (PRS) Oral Glucose Tolerance Test - Diabetes | Phase 4 | Not yet recruiting | University of Maryland, Baltimore | 400 | 2026-12-01 | 2026-02-18 |
| Heart-Kidney-Diabetes Multidisciplinary Care MOdels for CardiovascuLar Health In Patients With Chronic Kidney DiSease and Diabetes: A PragmaTIC Cluster Randomized Controlled Trial (HOLISTIC) The intervention with the MCM is Kidney-Heart GDMT initiation and titration for dose optimization (as clinically tolerated), within 4 months of enrollment in the study. - Chronic Kidney Disease, Type II Diabetes | Phase 4 | Not yet recruiting | Baim Institute for Clinical Research | 570 | 2026-12-01 | 2026-09-10 |
| Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance Testosterone cypionate - Prostate Cancer, Hypogonadism, Male | Phase 4 | Recruiting | University of Miami | 35 | 2026-11-30 | 2026-11-02 |
| CYTALUX Dose Extension Study CYTALUX (pafolacianine) injection - Cancer in the Lung, Ovarian Cancer | Phase 4 | Not yet recruiting | On Target Laboratories, LLC | 106 | 2026-11-15 | 2026-11-09 |
| Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication - Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies | Phase 4 | Not yet recruiting | University of Michigan | 600 | 2026-11-01 | 2026-10-21 |
| Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia Lower-Extremity Revascularization, Donaperminogene Seltoplasmid - Chronic Limb-Threatening Ischemia, Diabetic Foot Ulcer | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 180 | 2026-10-20 | 2026-09-18 |
| Iopidine to Decrease Intraocular Pressure Rise After Injections Apraclonidine 1.0% ophthalmic solution - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Not yet recruiting | Retina Consultants of Delmarva | 120 | 2026-10-01 | 2026-10-23 |
| Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab) - MAFLD in Prediabetes and Diabetes | Phase 4 | Not yet recruiting | Sherihan AboElyazed Mohamed Khalil | 66 | 2026-10-01 | 2026-10-23 |
| PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses Orforglipron - Diabete Type 2, Pharmacogenomic Drug Interaction | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 100 | 2026-10-01 | 2026-08-31 |
| A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India Selpercatinib - Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 4 | Not yet recruiting | Eli Lilly and Company | 30 | 2026-10-01 | 2026-10-08 |
| PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon) Eroxon®, tadalafil - Type 2 Diabetes, Type 2 Diabetes (T2DM) | Phase 4 | Suspended | University of Miami | 30 | 2026-10-01 | 2026-09-28 |
| Role of Finerenone in African American Veterans With Diabetic Kidney Disease Finerenone 10 MG, Empagliflozin 10 MG - Diabetic Kidney Disease | Phase 4 | Not yet recruiting | Washington D.C. Veterans Affairs Medical Center | 30 | 2026-10-01 | 2026-08-21 |
| Randomized, Controlled Study to Investigate the 12-month Efficacy and Safety of Resveratrol Vitamin Supplements in Patients With Non-proliferative Diabetic Retinopathy Without Center Involved Diabetic Macular Edema (REVOLUTION Study) Resveratrol-Containing Vitamin Supplement - Diabetic Retinopathy, Non Proliferative Diabetic Retinopathy | Phase 4 | Completed | University of Athens | 100 | 2026-09-30 | 2026-10-09 |
| MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes Montelukast, Placebo - Diabetes, Kidney Disease | Phase 4 | Not yet recruiting | University of Colorado, Denver | 110 | 2026-09-01 | 2026-07-06 |
| An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab veligrotrug (LUMVOA™) - Thyroid Eye Disease | Phase 4 | Not yet recruiting | Viridian Therapeutics, Inc. | 30 | 2026-09-01 | 2026-09-21 |
Showing 20 of 2698. Sign in to see all of them.
Diabetes Mellitus, Type 2 (1185) · Diabetes Mellitus (737) · Diabetes Mellitus, Type 1 (191) · Insulin Resistance (151) · Hypertension (122) · Polycystic Ovary Syndrome (120) · Obesity (112) · Coronary Artery Disease (75) · Diabetic Nephropathies (65) · Hypogonadism (62) · Renal Insufficiency, Chronic (56) · Cardiovascular Diseases (55) · Diabetic Foot (55) · Prediabetic State (54) · Diabetic Retinopathy (52)
Nutritional and Metabolic Diseases (1976) · Metabolic Diseases (1939) · Glucose Metabolism Disorders (1883) · Diabetes Mellitus (1296) · Urogenital Diseases (491) · Female Urogenital Diseases and Pregnancy Complications (462) · Pathological Conditions, Signs and Symptoms (439) · Cardiovascular Diseases (429) · Female Urogenital Diseases (428) · Vascular Diseases (380) · Gonadal Disorders (289) · Neoplasms (271) · Male Urogenital Diseases (264) · Immune System Diseases (256)
Metformin (301) · Insulin Glargine (209) · Sitagliptin Phosphate (117) · dapagliflozin (114) · Insulin (89) · Insulin Aspart (89) · Pioglitazone (86) · empagliflozin (79) · Liraglutide (71) · glimepiride (65) · Exenatide (61) · Insulin Lispro (55) · Insulin Detemir (54) · Vildagliptin (52) · semaglutide (44)
Sanofi (100) · Novo Nordisk A/S (90) · Eli Lilly and Company (42) · Novartis Pharmaceuticals (33) · AstraZeneca (29) · Emory University (26) · GlaxoSmithKline (26) · Seoul National University Bundang Hospital (22) · University of Colorado, Denver (18) · Novartis (17) · The University of Texas Health Science Center at San Antonio (17) · Steno Diabetes Center Copenhagen (16) · Takeda (16) · Seoul National University Hospital (15) · University Magna Graecia (15)
United States (725) · China (282) · South Korea (175) · Italy (139) · Germany (129) · Denmark (126) · United Kingdom (121) · Canada (115) · France (96) · Spain (91) · Netherlands (82) · Brazil (79) · Sweden (72) · Mexico (69) · Japan (66)
Stefano Palomba, MD (14) · Guillermo Umpierrez, MD (12) · Francesco Orio, MD (8) · Achille Tolino, MD (7)
PMID 33166419, PMID 39963952, PMID 38682786, PMID 32501595, PMID 35224730, PMID 37435938, PMID 34693515, PMID 38770818, PMID 25765670, PMID 32803882, PMID 39641307, PMID 40875095, PMID 15613435, PMID 15827109, PMID 17513708, PMID 18305265, PMID 19156705, PMID 19366972, PMID 19454394, PMID 20536957, PMID 20923490, PMID 21228246, PMID 22002075, PMID 22773702, PMID 22775317, PMID 23435159, PMID 23857221, PMID 24445038, PMID 27483065, PMID 27529295, PMID 27611736, PMID 28143456, PMID 28981994, PMID 29600824, PMID 30084288, PMID 30206821, PMID 30243803, PMID 30521533, PMID 30779243, PMID 31139483, PMID 31802967, PMID 31865758, PMID 32411431, PMID 32427087, PMID 33107592, PMID 33210751, PMID 33293204, PMID 33347618, PMID 34605781, PMID 34732660
2015 (20), 2014 (14), 2009 (11), 2008 (10), 2016 (10), 2018 (8), 2019 (8), 2005 (6), 2017 (5), 2023 (4), 2025 (4), U54RR014616 (3), R01DK077166 (2), R01DK107680 (2), R01NS057594 (2)